{"entity":{"id":"evandro-de-azambuja","kind":"person","name":"Evandro de Azambuja","aka":[],"tldr":"Evandro de Azambuja is a breast oncologist who studies heart safety of HER2-targeted therapy in BIG trials.","summary":"Evandro de Azambuja is Head of the Medical Support Team at Institut Jules Bordet in Brussels and a medical oncologist working with the Breast International Group (BIG). His specialisms are breast cancer, cardio-oncology and adjuvant HER2 therapy. He works on adjuvant HER2 trials and the cardiac safety of trastuzumab-based therapy. His papers include the NeoALTTO phase 3 trial of lapatinib with trastuzumab in HER2-positive early breast cancer and its link between pathological complete response and outcomes, the New England Journal of Medicine report of adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer, and an analysis of trastuzumab-associated cardiac events at long-term follow-up in the HERA trial. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Azambuja%20E%5BAuthor%5D%20cardiotoxicity%20trastuzumab"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":["cardio-oncology"],"targets":[],"drugs":[],"companies":["big"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of Medical Support Team, Institut Jules Bordet; Medical Oncologist","institutionId":"big","specialisms":["Breast cancer","Cardio-oncology","Adjuvant HER2 therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=de%20Azambuja%20E%5BAuthor%5D%20cardiotoxicity%20trastuzumab"}],"papers":[{"title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response","journal":"The Lancet Oncology","year":2014,"doi":"10.1016/s1470-2045(14)70320-1"},{"title":"Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer","journal":"New England Journal of Medicine","year":2017,"doi":"10.1056/nejmoa1703643"},{"title":"Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)","journal":"Journal of Clinical Oncology","year":2014,"doi":"10.1200/jco.2013.53.9288"},{"title":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2105215","doi":"10.1056/NEJMoa2105215"}],"orcid":"0000-0001-9501-4509"},"route":"/people/evandro-de-azambuja/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"technology":[{"id":"cardio-oncology","kind":"technology","name":"Cardio-oncology","route":"/technologies/cardio-oncology/"}],"company":[{"id":"big","kind":"company","name":"Breast International Group (BIG)","route":"/companies/big/"}],"paper":[{"id":"paper-olympia-nejm-2021","kind":"paper","name":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","route":"/key-papers/paper-olympia-nejm-2021/"}],"institution":[{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","route":"/institutions/institut-jules-bordet/"}]}}